Clinical remission · people with active UC
Cannabidiol showed no clear difference in clinical remission at 10 weeks compared with placebo (low certainty).
1 finding from 1 review
Clinical response at 10 weeks · people with active UC
Cannabidiol showed no clear difference in clinical response at 10 weeks compared with placebo (low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · people with active UC
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
Adverse events · people with active UC
Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with active UC
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients achieving clinical response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Short‐Form 36 health survey (SF‐36) · Patients with active Crohn's disease
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes proportion of patients achieving clinical remission compared with placebo oil (very low certainty).
1 finding from 1 review